U.S. Government Exercises Option for Supply of Additional Smallpox Vaccines from Bavarian Nordic
COPENHAGEN, Denmark, May 7, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the final USD 12 million option remaining under the USD 202 million order for JYNNEOS® (Smallpox and Monkeypox Vaccine, Live, Non-replicating) awarded in April 2020.
This option covers the supply of additional liquid-frozen JYNNEOS doses which will be manufactured in the Company’s new fill and finish facility during 2021. In addition, the total contract of USD 202 million for procurement includes manufacturing of bulk vaccine, which is revenue recognized in the years 2020-2022.
Paul Chaplin, President and CEO of Bavarian Nordic said: “Our contracts with BARDA have been foundational for the establishment of a sustainable manufacturing and supply of critical vaccines for protecting the United States of America. This year, we are launching operations in our newly established fill and finish plant, which enables us to bring the final step of commercial manufacturing of JYNNEOS in-house as the first product on the line, marking a significant milestone in our long-standing partnership with the U.S. government.”
The contents of this announcement do not affect the company’s expectations for the financial results for 2021.
This project has been supported in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700019C.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. government of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine based on an in-licensed capsid virus-like particle technology. The vaccine candidate, ABNCoV2, is currently being investigated in clinical trials. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, email@example.com, Tel: +1 781 686 9600
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Klövern ansöker om avnotering av bolagets aktier och utser ny VD24.6.2021 16:18:32 CEST | Pressemelding
Styrelsen i Klövern AB (publ) (”Klövern”) ansöker om avnotering av Klöverns aktier från Nasdaq Stockholm. Eva Landén har utsetts till ny VD för Klövern. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade erbjudandet ovillkorat den 15 juni 2021. Corem kontrollerar per dagens datum cirka 95,0 procent av de utestående aktierna i Klövern och avser att påkalla tvångsinlösen av resterande aktier. Corem har även förlängt acceptperioden för erbjudandet till och med den 18 augusti 2021. Mot bakgrund av ovanstående, och på begäran av Corem, har styrelsen för Klövern beslutat att ansöka om avnotering av bolagets aktier från Nasdaq Stockholm. Sista dag för handel i Klöverns aktier vid Nasdaq Stockholm kommer att meddelas så snart Klövern erhållit besked om detta från Nasdaq Stockholm. På begäran av Corem har styrelsen i Klövern vidare utsett Eva Landén till ny VD för Klövern. Eva Landén är VD för Corem och
Klövern applies for delisting of the company’s shares and appoints new CEO24.6.2021 16:18:32 CEST | Press release
The Board of Directors of Klövern AB (publ) (”Klövern”) applies for delisting ofKlövern’sshares from Nasdaq Stockholm. Eva Landén has been appointed new CEO of Klövern. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Corem declared the offer unconditional on 15 June 2021. As of today, Corem controls approximately 95.0 percent of the outstanding shares in Klövern and intends to apply for compulsory redemption of the remaining shares. Corem has also extended the acceptance period för the offer to 18 August 2021. In light of the above, and at the request of Corem, the Board of Directors of Klövern has decided to apply for delisting of the company’s shares from Nasdaq Stockholm. The last day of trading in Klövern's shares will be announced as soon as Klövern has been informed thereof by Nasdaq Stockholm. Further, at the request of Corem, the Board of Directors of Klövern has appointed Eva Landén as new CEO of Klövern. Eva
Lantronix Announces SmartEdge Partner Program Award Winners24.6.2021 13:00:00 CEST | Press release
SmartEdge Partner Program Winners Are Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India and Enthu Technology Sdn. Bhd. IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, today announced the winners of its SmartEdge™ Partner Program Awards. The awards were given at Lantronix’s 2021 SmartEdge Partner Summit held virtually on June 23, 2021. Lantronix’s SmartEdge Partner Program Awards were given to winners in three categories: Distribution Partner, StrategicEdge Partner and Edge Partner covering three regions: North America, Europe/Middle East/Africa and Asia Pacific. The winners are: North America North America Distributor Partner of the Year: Tech Data North America StrategicEdge Partner of the Year
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-06-29BondsKOMMUNINVEST I SVERIGE: 2302. SE0009662943. 2023-02-22 KOMMUNINVEST I SVERIGE: 2410, SE0010469205, 2024-10-02 KOMMUNINVEST I SVERIGE: 2602, SE0013745452, 2026-02-04 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-06-29Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)2302: 500 mln SEK +/-250 mln SEK 2410: 500 mln SEK +/-250 mln SEK 2602: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)2302: 500 mln SEK per bid 2410: 500 mln SEK per bid 2602: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-07-01Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Condition
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-06-30CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-12-30 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-06-17 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-06-30Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-07-02BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 KINGDOM OF SWEDEN: REGS (GREEN), XS2226974504, 2030-09-09 Bid date2021-07-02Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 500 mln SEK +/-250 mln SEK 1063: 500 mln SEK +/-250 mln SEK REGS (GREEN): 250 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 500 mln SEK per bid 1063: 500 mln SEK per bid REGS (GREEN): 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-07-06Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-06-24 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK COVERED BONDS24.6.2021 12:05:00 CEST | Press release
Bid procedure, 2021-07-01BondsSWEDBANK HYPOTEK AB: 196. SE0015244991. 2026-03-18 STADSHYPOTEK AB: 1591, SE0013882644, 2026-06-01 SWEDISH COVERED BOND: 147, SE0009383664, 2026-06-17 SKANDINAVISKA ENSKILDA: 580, SE0013101722, 2025-12-17 LANSFORSAKRINGAR HYPOTEK: 521, SE0015503446, 2028-09-20 DANSKE HYPOTEK AB: 2212, SE0010297085, 2022-12-21 NORDEA HYPOTEK AB: 5536, SE0013358439, 2026-09-16 Bid date2021-07-01Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)196: 400 mln SEK +/-200 mln SEK 1591: 1900 mln SEK +/-950 mln SEK 147: 700 mln SEK +/-350 mln SEK 580: 500 mln SEK +/-250 mln SEK 521: 600 mln SEK +/-300 mln SEK 2212: 500 mln SEK +/-250 mln SEK 5536: 400 mln SEK +/-200 mln SEK Highest permitted bid volume (corresponding nominal amount)196: 400 mln SEK per bid 1591: 1900 mln SEK per bid 147: 700 mln SEK per bid 580: 500 mln SEK per bid 521: 600 mln SEK per bid 2212: 500 mln SEK per bid 5536: 400 mln SEK per bid Lowest permitted bid volume (co